AngioLab, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1999-06-03
- Employees
- 16
- Market Cap
- -
- Website
- http://www.angiolab.co.kr
A Study to Evaluate the Efficacy and Safety of ALH-L1005 in Patients With Chronic Periodontitis
Phase 2
Completed
- Conditions
- Chronic Periodontitis
- Interventions
- Drug: PlaceboDrug: ALH-L1005 600mg/dayDrug: ALH-L1005 1,200mg/day
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- AngioLab, Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT04503746
- Locations
- 🇰🇷
AngioLab, Inc., Daejeon, Daejeon Gwangyeogsi, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH
Phase 2
Completed
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Drug: Placebo oral tabletDrug: ALS-L1023 1,200mgDrug: ALS-L1023 1,800mg
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- AngioLab, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04342793
- Locations
- 🇰🇷
Hanyang University Seoul Hospital, Seoul, Korea, Republic of
Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD
Phase 2
Completed
- Conditions
- Age-Related Macular Degeneration
- Interventions
- First Posted Date
- 2018-10-31
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- AngioLab, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT03725501
- Locations
- 🇰🇷
AngioLab, Inc., Daejeon, Daejeon Gwangyeogsi, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath